KCT0007442
Not yet recruiting
未知
Prospective, multicenter, open-labeled, phase II study of clinical effect of the combination of metformin and standard chemotherapy in patient with newly diagnosed with T-cell lymphoma and the role of AMP-activated protein kinase (AMPK)
ConditionsNeoplasms
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Neoplasms
- Sponsor
- Kyungpook National University Hospital
- Enrollment
- 60
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •not applicable
Exclusion Criteria
- •not applicable
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A phase II, open-label, prospective, multicenter study to evaluate theefficacy and safety of subsequent treatment with the Zevalin(ibritumomab tiuxetan) study in patients with follicular grade I-IIlymphoma after 4 cycles of Fludarabine-Mitoxantrone-Rituximab(FMR) therapy. - NDEUCTR2006-004850-26-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
Active, not recruiting
Phase 1
A phase II, multicentre, open label, prospective, interventional study to evaluate the sperm DNA fragmentation in idiopathic male infertility before and after treatment with Gonal-f PEN 900 IU. - NDIdiophatic male infertilityMedDRA version: 9.1Level: SOCClassification code 10014698EUCTR2010-020196-23-ITMERCK SERONO SPA
Active, not recruiting
Phase 1
A study evaluating the safety and efficacy of the combination of tirabrutinib (GS-4059) and entospletinib with and without obinutuzumab in subjects with chronic lymphocytic leukemiaAdults with relapsed or refractory chronic lymphocytic leukemiaMedDRA version: 20.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-002768-15-DEGilead Sciences, Inc.36
Active, not recruiting
Phase 1
A study evaluating the safety and efficacy of the combination of tirabrutinib (GS-4059) and idelalisib with and without obinutuzumab in subjects with chronic lymphocytic leukemiaEUCTR2015-003909-42-DEGilead Sciences, Inc.36
Active, not recruiting
Not Applicable
Prospective, open label, multi center phase II clinical trial with neoadjuvant chemotherapy in addition with Sorafenib in patients with primarily advanced ovarian cancer (FIGO IIIC + IV) and ascites (>500ml) - primofenib-07Ovarian CancerStage FIGO IIIc and IV with more than 500 ml ascitesMedDRA version: 9.1Level: LLTClassification code 10057529Term: Ovarian cancer metastaticEUCTR2006-004644-24-DEniversity of Bonn102